Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients, age ≥ 18 years~* Advanced or metastatic breast cancer, histologically confirmed~* Documented HER2 overexpression (IHC 3+ and/or FISH positive)~* At least one measurable lesion according to RECIST criteria. Patients with bone-only lesions are not eligible for study entry~* Documented disease progression~* Patients may have no more than 1 line of palliative treatment, however prior therapies must include trastuzumab in adjuvant or metastatic setting~* Life expectancy of at least 12 weeks~* Performance status 0-1~* Cardiac ejection fraction \>= 50% as measured by echocardiogram or MUGA scan~* Adequate hematology, liver and renal function~Exclusion Criteria:~* Pregnant or lactating women~* Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent~* Severe cardiac disease (uncontrolled angina, arrhythmia, chronic heart failure (CHF) or cardiac disease requiring a device)~* Ejection fraction below the institutional normal limit~* Maximum cumulative dose of 360 mg/m2 for doxorubicin and 720 mg/m2 for epirubicin~* Active bacterial, viral or fungal infection~* Patients with clinically apparent brain metastases~* Positivity for HIV, Hepatitis B or C~* History of other malignancy; patients who have been disease-free for 5 years~* Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy) or concurrent treatment with an investigational drug or participation in another clinical trial~* Known hypersensitivity to the study drugs Lapatinib and Caelyx or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caelyx/Lapatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).